Compare Natera Inc. Common Stock (NTRA) vs nVent Electric (NVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs nVent Electric — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while nVent Electric trades at $148.5 (market cap $24.72B). The key difference: Natera Inc. Common Stock is far larger — about 2.3× nVent Electric's market cap, and nVent Electric pays a 0.55% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and nVent Electric for 14 Days on average.
| NTRA | NVT | |
|---|---|---|
Market Cap | $57.03B | $24.72B |
Volume | 1,131,157 | 2,529,194 |
Sector | Health | Industrials |
52-Week High | $425.64 | $184.34 |
52-Week Low | $179.42 | $94.99 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $56.18B | $26.10B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
NVT trades at $161.47, down 0.8% with a bullish technical outlook and strong institutional support. The company demonstrates robust earnings momentum with three consecutive quarterly beats and a 61% YTD surge driven by AI data-center demand. Recent developments include the $1.75 billion acquisition of Maverick Power and a strategic collaboration with AMD on cooling solutions for AI infrastructure, positioning NVT for continued growth in the expanding data center market.
While NVT's premium valuation (P/E 44.85) and rising competition present risks, strong analyst consensus (85% buy rating) with a $203.86 price target suggests 26% upside potential. The company's expanding AI infrastructure portfolio and solid cash flow generation support long-term growth, though investors should monitor tariff impacts and valuation compression risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About nVent Electric
nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →
